BLOG

cancer_network

Nicholas Coupe, MBBS, PhD, Provides Update on Phase 2 Study of IMM60 in Advanced Melanoma/NSCLC

PORT-2 is an activator of this population. It has direct impact against tumors in terms of upregulating PD-L1 expression, which we know is favorable because it can